Pennington Biomedical Research Center
Baton Rouge, Louisiana, 70808, United States
NCT Number: NCT02068144
The purpose of this study is to determine the health benefits of cranberry extract in people who are at risk for diabetes and heart problems.
Looking for future studies?
Notify Me20 year and older
All sexes
Interventional
Not applicable
Baton Rouge, Louisiana, 70808, United States
This study will be a double-blinded, randomized, placebo-controlled, pilot study in which subjects with pre-diabetes will be randomized to receive either placebo or Cranberry extract for a total of 8 weeks of treatment. Each subject will continue on the same dosage of cranberry extract or matching placebo for the entire duration of treatment. Comparisons for insulin sensitivity, endothelial function, and markers of inflmmation and oxidative stress will be made between the 2 groups pre and post intervention.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants will drink one 15.2 oz bottle of Cranberry Extract beverage daily for 8 weeks.
Participants will drink one 15.2oz bottle of placebo beverage daily for 8 weeks.
Time frame: 8 weeks +/- 2 days
Insulin sensitivity is tested using a 120 mU/m2 hyperinsulinemic-euglycemic clamp at 100mg/dL glucose over 2 hours at weeks 0 and 8
Time frame: 8 weeks +/- 2 days
Endothelial function by peripheral arterial tone (PAT) with an endo-PAT device prior to week 0 and week 7 as a surrogate measure of atherosclerosis.
Time frame: 8 weeks +/- 2 days
Resting metabolic rate via indirect calorimetry will be measured using a Deltatrac II Metabolic cart at week 0 and week 8 as part of the hyperinsulinemic euglycemic clamp.
Time frame: 10 weeks +/- 2 days
A comprehensive metabolic profile (CHEM 15) will be obtained at screening and then at week 8.
Time frame: 8 weeks +/- 2 days
Body weight will be assessed at baseline and week 8.
Time frame: 8 weeks +/- 2 days
A 2 hr OGTT will be performed prior to week 0 and at week 7
Time frame: 8 weeks +/- 2 days
Levels of nitric oxide will be assessed at baseline and after 8 weeks of intervention
Time frame: 8 weeks +/- 2 days
Levels of endothelin 1 will be assessed at baseline and after 8 weeks of intervention
Time frame: 8 weeks +/- 2 days
Levels of oxidized LDL will be assessed at baseline and after 8 weeks of intervention
Time frame: 8 weeks +/- 2 days
Levels of LOX-1 (Lectin-like oxidized low density lipoprotein-1) will be assessed at baseline and after 8 weeks of intervention
Time frame: 8 weeks +/- 2 days
Levels of 8-isoprostanes will be assessed at baseline and after 8 weeks of intervention
Time frame: 8 weeks +/- 2 days
Levels of malondialdehyde will be assessed at baseline and after 8 weeks of intervention
Time frame: 8 weeks +/- 2 days
Levels of advanced glycation end products will be assessed at baseline and after 8 weeks of intervention
Time frame: 8 weeks +/- 2 days
Levels of Apo A1 will be assessed at baseline and after 8 weeks of intervention
Time frame: 8 weeks +/- 2 days
Levels of Paraoxonase will be assessed at baseline and after 8 weeks of intervention
Time frame: 8 weeks +/- 2 days
Levels of Adiponectin will be assessed at baseline and after 8 weeks of intervention
Time frame: 8 weeks +/- 2 days
Levels of C-reactive protein (CRP) will be assessed at baseline and after 8 weeks of intervention
Time frame: 8 weeks +/- 2 days
Levels of TNFα will be assessed at baseline and after 8 weeks of intervention
Pennington Biomedical Research Center
Other
The Effect of Daily Dietary Supplementation With Cranberry Extract on Modulation of Cardiovascular Risk Factors in Obese, Insulin Resistant Human Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04167761
Arterial Occlusive Diseases, Arteriosclerosis
Stanford, California, United States
View Trial DetailsNCT00428961
Arterial Occlusive Diseases, Arteriosclerosis
Kansas City, Missouri, United States
View Trial DetailsNCT00330733
Arterial Occlusive Diseases, Arteriosclerosis
Phoenix, Arizona, United States
View Trial DetailsNCT00544102
Arterial Occlusive Diseases, Arteriosclerosis
Bethesda, Maryland, United States
View Trial Details